Company
End-to-end diagnostic solutions for infectious diseases
Overview
Molecular biology assays for microbiology laboratories
ABL Texcell Diagnostics (formerly ABL Diagnostics), listed on Euronext Paris (ISIN FR001400AHX6), offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection by Polymerase Chain Reaction (PCR), UltraGene®, and for genotyping through DNA sequencing, DeepChek®: a very sensitive, robust and sustainable technology allowing precise identification of relevant genomic variations such as single nucleotide polymorphisms (SNP), amino-acid mutations and quasispecies like variants of concern, with known impact on disease prognosis, drug efficacy or pathogen activity.
These products generate recurring revenues and cover one of the largest portfolios of microbiology applications, growing year after year to meet the needs of the market, with a primary focus on HIV (CE-IVD marked target-specific assays covering all relevant genes used for drug resistance assessment, such as reverse transcriptase, protease and integrase, and whole genome kits), SARS-CoV-2, tuberculosis (a CE-IVD marked multiplex assay targeting genes relevant for first-line, second-line and new-drug resistance), viral hepatitis B and C, 16S/18S rRNA for taxonomy and microbiome analyses, and other viral and bacterial targets. Please consult our team about the registration status of our products in your territory.
We commercialize our entire line of products worldwide through our own sales team and a network of exclusive distributors active on all continents. Our clients are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiology content in constant expansion.
We also develop, manufacture and market kits for clinical specimen collection, MediaChek®, and digital solutions like Nadis®, a CE-marked Electronic Medical Record (EMR) system used in France in more than 200 hospitals managing patients infected by HIV or viral hepatitis.
History
Key milestones
Each milestone links to the related announcement in the newsroom.
- 2019AdvancedDx Biological Laboratories USA Inc., wholly owned subsidiary, starts operating in the United States.
- Sept 2019Quality management system compliant with ISO 13485:2016.
- Oct 2021Advanced Biological Laboratories S.A. acquires a controlling stake in Etablissements Fauvet Girel, listed on Euronext Paris. Read more
- Mar 2022Etablissements Fauvet Girel is renamed ABL Diagnostics. Read more
- May 2022Nominal value of the shares divided by 8; new ISIN code FR001400AHX6. Read more
- Sept 2022Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merges into ABL Diagnostics S.A. Read more
- Oct 2022ISO 13485:2016 certification for the design, development, production, distribution, training and support of IVD medical devices.
- July 2026BSI confirmed as notified body for the IVDR transition of the CE-IVD medical devices. Read more ↗
- July 2026Selected by the Évry Commercial Court to acquire the operations of Texcell. Read more ↗
- Sept 2026ABL Diagnostics becomes ABL Texcell Diagnostics. Read more ↗
Governance
Board of directors
Quality & conformity
Products suitable for in-vitro diagnostics
To ensure full control of our quality standards, most of our products are produced or assembled in-house, in our laboratories in Marseille (France) or in the facilities of our parent company in Luxembourg, which received the “Made in Luxembourg” label in June 2021.
- ISO 13485:2016
Compliant with ISO 13485:2016 since September 2019, using European ISO 13485 certified suppliers for the components of our products, and certified since October 2022 with the scope “Design, development, production, distribution, training and support of in-vitro diagnostic medical devices”.
- CE-IVD · IVDR
A panel of our products is CE-IVD marked according to the European Directive 98/79/EC. Their transition to the EU Regulation 2017/746 on in-vitro diagnostic medical devices (IVDR) is carried out with BSI as notified body.
Read the announcement (opens EIN Presswire)
